Growth minority (consumer-heavy) fund research profile
Lighthouse Funds is an India-focused growth-stage private-equity manager backing category-leading consumer and healthcare businesses, with additional exposure to specialty manufacturing and digital transformation. Its model combines growth capital with hands-on operating support.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Lighthouse Funds uses a growth minority (consumer-heavy) approach across Consumer brands, health, specialty mfg.
Current evidence
Lighthouse’s 2025 newsroom records investments in Knest Manufacturing, Kalki Fashion, Parsons Nutritionals and The Bombay Canteen, while the current manager page identifies Lighthouse India Fund IV as its active Category II AIF and names current portfolio companies including Bikaji, Duroflex, Tynor and Poly Medicure.
Strategy
Growth minority (consumer-heavy)
Sector focus
Consumer brands, health, specialty mfg
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Lighthouse’s 2025 newsroom records investments in Knest Manufacturing, Kalki Fashion, Parsons Nutritionals and The Bombay Canteen, while the current manager page identifies Lighthouse India Fund IV as its active Category II AIF and names current portfolio companies including Bikaji, Duroflex, Tynor and Poly Medicure.
Investor questions
Lighthouse Funds is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth minority (consumer-heavy), with a sector focus of Consumer brands, health, specialty mfg. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Lighthouse Funds in the reviewed public sources: Bikaji Foods, Duroflex, Tynor, Poly Medicure, Medikabazaar, Ferns N Petals, Aqualite, Kushal’s, Parsons Nutritionals, Kalki Fashion, Knest Manufacturing, Safari Industries, The Bombay Canteen. It does not represent a complete current portfolio unless the manager has published one.
Lighthouse’s public record includes disclosed outcomes such as 7x on Dhanuka Agritech, 3x on Unibic and 2.3x on Suraksha Diagnostics, plus exits and partial exits in Bikaji, Nykaa and Tynor. These are deal-level or manager-reported outcomes, not fund-level net returns. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: IFC described Lighthouse India Fund IV as targeting $400M, and NIIF disclosed a ₹400 Cr commitment. The manager also states Fund IV is its first scheme under Lighthouse India Investment Trust.. Public terms or access information: Growth transactions in consumer, healthcare and specialty manufacturing; current cheque, ownership and reserve ranges are not uniformly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Mukund Krishnaswami, Sachin Bhartiya. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund IV allocation and fund-level returns are not publicly disclosed; the current India platform is a growth-stage PE strategy focused on consumer and healthcare..
2025-10-10: Lighthouse’s 2025 newsroom records investments in Knest Manufacturing, Kalki Fashion, Parsons Nutritionals and The Bombay Canteen, while the current manager page identifies Lighthouse India Fund IV as its active Category II AIF and names current portfolio companies including Bikaji, Duroflex, Tynor and Poly Medicure.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.